Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Secondary bladder cancer after RT not uncommon in prostate cancer patients

21 Apr 2026 bởi

A secondary bladder cancer (SBC) rarely occurs among patients with localized prostate cancer who have been treated with radiotherapy (RT), but the incidence rate is not insignificant, reports a study presented at EAU 2026. When it does appear, it usually becomes the primary cause of death in this population.

Secondary bladder cancer after RT not uncommon in prostate cancer patients

21 Apr 2026

Residential radon exposure linked to ovarian cancer

20 Apr 2026

Women residing in homes with high radon levels may be at increased risk of ovarian cancer, as suggested in a study.

Residential radon exposure linked to ovarian cancer

20 Apr 2026

Young adults with glomerular disease at increased risk of cancer

19 Apr 2026

Glomerular disease is associated with an increased risk of cancer, particularly among younger patients who are typically excluded from screening programs, according to a retrospective study.

Young adults with glomerular disease at increased risk of cancer

19 Apr 2026

Cannabis may reduce risk of some skin cancers

18 Apr 2026 bởi

The use of cannabis appears to result in a lower incidence of basal cell carcinoma (BCC) over 10 years, but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), suggests a recent study presented at AAD 2026.

Cannabis may reduce risk of some skin cancers

18 Apr 2026

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Patients with cutaneous malignant melanoma (CMM) whose tumour is located in the head and neck (HN) are at greater risk of all-cause and cancer-specific mortality than those with tumours found in the trunk, reveals a study.

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Pegfilgrastim administered 72 h postchemo lessens bone pain

17 Apr 2026

Administrating pegfilgrastim 72 h after chemotherapy, compared with 24- and 48-h administration, results in reduced pegfilgrastim-induced bone pain (PIBP) and does not appear to increase the rates of neutropenia or febrile neutropenia (FN), reports a study.

Pegfilgrastim administered 72 h postchemo lessens bone pain

17 Apr 2026

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026 bởi

Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

13 Apr 2026 bởi

Biomarker testing where appropriate and novel tailored combination therapies targeting multiple pathways simultaneously may address the high unmet need and optimize treatment outcomes in hormone receptor–positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients who develop resistance or have disease recurrence while on endocrine-based therapy (ET), said Professor Sherko Kümmel of the Interdisciplinary Breast Unit Clinics, Essen-Mitte, Germany, who spoke at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

13 Apr 2026

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026 bởi

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026

Tin tức & Cập nhật

Xem bài viết Ung thư

Xem

Chuyên ngành:

Secondary bladder cancer after RT not uncommon in prostate cancer patients

Secondary bladder cancer after RT not uncommon in prostate cancer patients

Residential radon exposure linked to ovarian cancer

Residential radon exposure linked to ovarian cancer

Young adults with glomerular disease at increased risk of cancer

Young adults with glomerular disease at increased risk of cancer

Cannabis may reduce risk of some skin cancers

Cannabis may reduce risk of some skin cancers

Head and neck tumours linked to increased mortality in CMM patients

Head and neck tumours linked to increased mortality in CMM patients

Pegfilgrastim administered 72 h postchemo lessens bone pain

Pegfilgrastim administered 72 h postchemo lessens bone pain

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Gotistobart a chemo-free option for metastatic sqNSCLC

Gotistobart a chemo-free option for metastatic sqNSCLC

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Perioperative EV plus pembro tied to better outcomes in patients with MIBC